Abstract 326P
Background
Exercise is suggested to reduce the recurrence risk in individuals with breast cancer. Evidence regarding relevant physiological mechanisms remains scarce. Here, we examined the association of inflammatory biomarkers with predicted recurrence events.
Methods
The Optitrain randomized controlled trial consisted of 240 patients undergoing chemotherapy for primary breast cancer randomised to interventions entailing biweekly supervised concurrent resistance exercise and high-intensity interval training (RT-HIIT), or concurrent aerobic exercise and HIIT (AT-HIIT), or usual care (UC) between 2013-2016. At baseline and the one-year follow-up, 96 inflammatory protein biomarkers were assessed using the Olink® Proximity Extension Assay Oncology Panel. Group differences were estimated using analysis of covariance adjusted for baseline levels. Recurrence outcomes were obtained from National Swedish registers. Event probabilities were predicted from cox-proportional hazards models adjusted for age, menopause, BMI, tumour characteristics, and taxane treatment. Associations between survival probabilities and inflammatory markers were examined using Pearson’s correlation.
Results
When comparing RT-HIIT and UC, exploratory differences across several C-C-motif chemokine ligands were found (CCL2, CCL3, CCL4, CCL13, CCL20, CCL23). Moreover, DCN, ICOSLG, soluble CD8 and CD4, CX3SL1, CXCL10, CD70, CD83, CSF-1, HGF, NCR1, PD-L2, PIGF, PTN, TNFRSF12A, and TNFRSF21S differed across groups (p<0.2). When examining event probabilities, CD70, soluble CD4, CCL2, CCL3, CCL4, CCL13, CCL20, and CCL23 at the one-year follow-up examinations formed a cluster of a weakly increased risk in recurrence-related events. The strongest associations between event probabilities and biomarkers of inflammation were recorded for distant recurrence-free interval events.
Conclusions
Explorative analyses assessing the interplay of systemic inflammation, exercise, and predicted event probabilities suggested a cluster of inflammatory biomarkers affected by exercise and positively correlated with recurrence-related predicted event probabilities.
Clinical trial identification
NCT02522260, August 13, 2015.
Editorial acknowledgement
Legal entity responsible for the study
Region Stockholm.
Funding
1. The Swedish Cancer and Traffic Accident Foundation (CTRF) (grant number F-C-001225) 2. Swedish Cancer Foundation (grant number 130452) 3. Radiumhemmet Research foundation (grant number 131242) 4. Karolinska Institutet School of Caring Sciences (grant number 04960/2012).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
334P - Cardiovascular events related to CDK4/6 inhibitors: A systematic review and safety meta-analysis of randomized controlled trials
Presenter: Louis Boismoreau
Session: Poster session 14
335P - First-in-human phase I/IIa clinical trial of ZV0203, a novel pertuzumab-based antibody-drug conjugate (ADC), in patients (pts) with Her2 positive advanced solid tumors
Presenter: Fengjuan Lin
Session: Poster session 14
336P - Determination of the most common hereditary mutations associated with breast cancer and ovarian cancer in the population of Ukrainian women
Presenter: Dmytro Nehrulia
Session: Poster session 14
337P - Is presence of molecular residual disease after pathologic complete response associated with relapse in inflammatory breast cancer?
Presenter: Jennifer Chen
Session: Poster session 14
338TiP - EORTC-2129-BCG: Elacestrant for treating ER+/HER2- breast cancer patients with ctDNA relapse (TREAT ctDNA)
Presenter: Michail Ignatiadis
Session: Poster session 14
339TiP - A randomized trial of trastuzumab deruxtecan and biology-driven selection of neoadjuvant treatment for HER2-positive breast cancer (ARIADNE)
Presenter: Theodoros Foukakis
Session: Poster session 14
351P - Abemaciclib plus fulvestrant for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy: Subgroup analyses from the phase III postMONARCH trial
Presenter: Giampaolo Bianchini
Session: Poster session 14
352P - Cost-effectiveness of CDK4/6 inhibitors in first- vs second-line for advanced breast cancer (ABC) in the phase III SONIA trial (BOOG 2017-03)
Presenter: Noor Wortelboer
Session: Poster session 14
353P - Clinical outcomes of treatment with CDK4/6 inhibitors in metastatic breast cancer among carriers of germline pathogenic variants in ATM, BRCA1, BRCA2, CHEK2, and PALB2
Presenter: Robert Scheel
Session: Poster session 14